{ }
001122334455554433221100
001122334455554433221100
Symbol ARGX
Name argenx SE
Currency USD
Sector Health Care
IndustryGroup Pharmaceuticals, Biotechnology & Life Sciences
Industry Biotechnology
Market NASDAQ Global Select
Country Netherlands
State
City Breda
Zipcode 4811 AH
Website http://www.argenx.com

Immunovant shares decline as UBS questions late-stage drug trial results

Shares of Immunovant fell 3.8% to $18.08 after UBS analysts deemed the late-stage data for its muscle disease drug, batoclimab, "unconvincing." While the drug showed some improvement in daily activities for myasthenia gravis patients, it did not meet expectations set by Argenx's Vyvgart. The company plans to focus on developing its other experimental drug, IMVT-1402, rather than seeking regulatory approval for batoclimab.

Immunovant shares decline after disappointing late-stage drug trial results

Shares in Immunovant fell 3.8% to $18.08 after UBS analysts described late-stage data for its muscle disorder drug, batoclimab, as "disappointing." The drug, tested for myasthenia gravis, showed some efficacy, but did not meet expectations set by Argenx's Vyvgart. Immunovant plans to focus on developing its other investigational drug, IMVT-1402, rather than seeking marketing authorization for batoclimab.

argenx stock downgraded to sell by deutsche bank

Deutsche Bank has downgraded Argenx SE (ARGX) stock to a Sell rating as of January 17, 2025. This decision reflects a shift in market sentiment towards the company, which is now facing increased scrutiny alongside competitors like Amgen (AMGN), Johnson & Johnson (JNJ), and Immunovant (IMVT).

analysts update recommendations and price targets for key european stocks

Analysts have made several notable recommendations, including JP Morgan maintaining an Underweight rating for Adecco with a reduced target of CHF 19.60, while Air France-KLM was downgraded by Barclays to Underweight with a target of EUR 7. ArgenX received a buy rating from HC Wainwright & Co, raising its target to 717 USD, and BioMérieux was upgraded to Outperform by Oddo BHF with a target of EUR 132. Other significant changes include upgrades for Deliveroo and Orange, while OVH Groupe remains a sell with a raised target of EUR 8.50.

european healthtech fundraising shows mixed results amid venture capital decline

In 2023, European companies raised €11.7 billion, a 9% increase from the previous year, driven by a 51% rise in IPOs and refinancings. The UK, Switzerland, and France led fundraising efforts, while venture capital fell by 19%, particularly impacting the French and British HealthTech sectors. Despite a challenging year, refinancing on secondary markets surged by 51%, with the Netherlands achieving the highest levels.
Trending
Subcategory
Countries:
Companies:
Currencies:
People:

Machinary offers a groundbreaking, modular, and customizable solution that provides advanced financial news and statistical analysis. Our platform goes beyond traditional quantitative analysis, offering users a comprehensive understanding of real-time market dynamics, event detection, and risk analysis.

Address

Newsletter

© 2025 by Machinary.com - Version: 1.0.0.0. All rights reserved

Layout

Color mode

Theme mode

Layout settings

Seems like the connection with the server has been lost. It can be due to poor or broken network. Please hang on while we're trying to reconnect...
Oh snap! Failed to reconnect with the server. This is typically caused by a longer network outage, or if the server has been taken down. You can try to reconnect, but if that does not work, you need to reload the page.
Oh man! The server rejected the attempt to reconnect. The only option now is to reload the page, but be prepared that it won't work, since this is typically caused by a failure on the server.